Related Experiment Video
Updated: Aug 7, 2026
The Mouse Round-window Approach for Ototoxic Agent Delivery: A Rapid and Reliable Technique for Inducing Cochlear Cell Degeneration
Published on: November 26, 2015
Therapeutic initiatives for the avoidance of aminoglycoside toxicity
Abstract:
Aminoglycosides continue to be indispensable in the management of serious and life-threatening aerobic gram-negative infections. On an annual basis in the United States, they are used in the management of four million patients. Despite their clinical utility, they continue to manifest a high profile of toxic side effects such as nephrotoxicity and ototoxicity with the rare occurrence of neuromuscular toxicity. Animal experimental models have been invaluable in elucidating the pathophysiologic mechanisms by which aminoglycosides damage the kidney and the inner ear. However, it is from clinical therapeutic experience and prospective clinical trials that we have been able to solidly define the risk factors that accentuate the development of aminoglycoside-related toxicity. The clinical toxicity of these agents can be kept to a minimum by ensuring the use of an appropriate dose, for periods of time not exceeding nine to ten days, in a well-hydrated, normokalemic patient. Special subpopulation groups such as the elderly, the obese, those with preexisting renal disease, or patients who need the concurrent use of other nephrotoxins, require special care in the monitoring of their aminoglycoside therapy to ensure a safe and effective clinical outcome.
Insights
Aminoglycosides are vital for treating severe gram-negative infections but can cause kidney and ear damage. Safe use involves appropriate dosing, short durations, and careful monitoring, especially in at-risk patients.
Area of Science:
- Pharmacology
- Nephrology
- Ototoxicology
Background:
- Aminoglycosides are critical for serious aerobic gram-negative bacterial infections, used in ~4 million US patients annually.
- Despite efficacy, aminoglycosides carry significant risks of nephrotoxicity and ototoxicity, with rare neuromuscular toxicity.
- Animal models aid understanding of aminoglycoside-induced kidney and inner ear damage.
Purpose of the Study:
- To define risk factors for aminoglycoside-related toxicity through clinical experience and trials.
- To outline strategies for minimizing aminoglycoside toxicity in clinical practice.
Main Methods:
- Review of clinical therapeutic experience.
- Analysis of prospective clinical trials.
- Identification of risk factors and protective measures.
Main Results:
- Clinical data solidifies understanding of risk factors for aminoglycoside toxicity.
- Optimal dosing, short treatment durations (9-10 days), and patient hydration/electrolyte balance minimize toxicity.
- Special populations (elderly, obese, renal disease, concurrent nephrotoxins) require vigilant monitoring.
Conclusions:
- Aminoglycoside toxicity can be minimized through careful patient selection and management.
- Adherence to recommended dosing and duration is crucial for safe and effective therapy.
- Close monitoring is essential for high-risk patient groups to ensure favorable clinical outcomes.
Related Concept Videos
01:14Prevention of Further Absorption of Poison
01:26Enhanced Elimination of Poison
Antidotes serve a crucial role in counteracting the effects of poison by inhibiting enzymes responsible for producing harmful drug metabolites. In some cases, these toxic metabolites can be neutralized by endogenous cosubstrates, which are maintained at specific concentrations to prevent interaction with cellular macromolecules and subsequent cell death.
Renal excretion is the...
01:15Determination of Multiple Dosing Parameters: Steady-State, Minimum and Maximum Concentrations
01:26Pharmacokinetics in Pediatric Patients: Drug Excretion
01:26Pharmaceutical Poisoning: Treatment Strategies
01:30Acute Kidney Injury IV: Diagnostic Studies and Prevention